Cerebrolysin

A porcine brain-derived peptide preparation used in some countries for stroke and dementia, with contested trial evidence.

What research shows

Cerebrolysin has a substantial trial literature across stroke and dementia, assessed in multiple systematic reviews, pooled analyses and European guidelines. Conclusions remain contested, and it holds no marketing authorisation in the regulators covered here, despite routine clinical use in several other countries.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.